Zai Lab (NASDAQ: ZLAB)
Zai Lab Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Zai Lab Company Info
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
News & Analysis
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Zai Lab's shares benefited from positive clinical trial news.
Why Shares of Zai Lab Are Dropping Wednesday
The company released a phase 3 trial regarding a non-small cell lung cancer therapy.
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
This company plans to be profitable soon, and its revenue is already spiking.
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out.
Why Shares of Zai Lab Soared This Week
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.
Buy These 2 Stocks to Access China's Huge Healthcare Market
BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.
3 Top Chinese Stocks to Watch in May
If you're looking for high-growth opportunities, China has plenty.
George Soros Bought These 2 Healthcare Stocks in the Third Quarter
The Soros Fund Management bought shares of both Express Scripts and Zai Lab Limited during the third quarter.
Valuation
Earnings Transcripts
Zai Lab Limited (ZLAB) Q2 2020 Earnings Call Transcript
ZLAB earnings call for the period ending June 30, 2020.
Zai Lab Limited (ZLAB) Q4 2019 Earnings Call Transcript
ZLAB earnings call for the period ending December 31, 2019.
Zai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript
ZLAB earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.